Stockholm, Sweden October 31, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has presented the latest findings…
Stockholm, Sweden, October 30, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…
Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctics co-founder, Professor Lars…
…
Stockholm, Sweden, October 11, 2024 – Pursuant to the instruction regarding the appointment of the Nomination Committee BioArctic AB’s (publ)…
Stockholm, September 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during September issued…
Stockholm, Sweden August 22, 2024 – British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic…
Stockholm, Sweden, August 15, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s second quarter report…
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Ministry…
Stockholm, Sweden, August 1, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…
Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented the latest findings…
Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will…
Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will present the…
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic…
Stockholm, June 28, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during June issued…
Stockholm, Sweden, June 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that that the…
Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry of Food…
Stockholm, 22 May 2024. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today,…
First BrainTransporter technology agreement signed
Events during the first quarter 2024
· Leqembi® was approved for the treatment of Alzheimers…
Stockholm, Sweden, May 15, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today said that they expect…
Stockholm, Sweden, May 15, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have…
Stockholm, Sweden, April 24, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…
Stockholm, Sweden, April 20, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai…
The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held…
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is excited to announce that BioArctic AB, a…
Stockholm April 16, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic…
Stockholm, Sweden, April 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) commitment to its Sustainable Innovation approach –…
Stockholm, Sweden, April 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has…
Stockholm, Sweden March 22, 2024 – BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral…
Stockholm, Sweden, March 19, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctics founder, Professor Lars…
Stockholm, Sweden, March 7, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a presentation including…
Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during February issued…
Stockholm, February 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and its partner…